VIRX Viracta Therapeutics, Inc.

26d ago, source: Seeking Alpha

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product ...

Peninsula biopharma wins 1st FDA approval for drug targeting type of brain cancer in kids

1d ago, source:

Branded as Ojemda, the newly approved drug targets a type of childhood brain cancer that has returned or isn't responding to ...

Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

1mon ago, source: Morningstar

Inc., extending cash runway into mid-Q1 2025 SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the ...

Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial

1mon ago, source: Nasdaq

About Viracta Therapeutics, Inc.Viracta is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide.

Viracta Therapeutics Stock (NASDAQ:VIRX), Analyst Ratings, Price Targets, Predictions

8d ago, source: Benzinga.com

There is no last upgrade for Viracta Therapeutics.

Promising Clinical Trial Results Reinforce Buy Rating for Viracta Therapeutics

7d ago, source:

Leerink Partners analyst Andrew Berens has maintained their bullish stance on VIRX stock, giving a Buy rating yesterday. Andrew Berens has ...

Viracta Therapeutics Inc (VIRX) Stock Records 31.45% Quarterly Movement

8d ago, source: newsheater

Based on Viracta Therapeutics Inc (VIRX), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at -1.56. The debt to equity ...

ZyVersa Therapeutics Inc’s (ZVSA) Stock: A Week-by-Week Analysis

2h ago, source: newsheater

The volatility ratio for the week is 9.28%, and the volatility levels for the last 30 days are 9.03% for ZyVersa Therapeutics Inc The simple moving average for the past 20 days is -11.24% for ZVSA’s ...

Viracta Therapeutics Inc VIRX

9d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial

1mon ago, source: Yahoo Finance

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers ...

Viracta Therapeutics, Inc. (VIRX)

1mon ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Viracta Therapeutics, Inc. (VIRX)

8d ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...